GleamWall
中文EN

EDIT Editas Medicine, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1650664 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.4%
TTM net income YoY63.9%
TTM EPS YoY77.0%
Revenue 3-yr CAGR26.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-151.7%
Net margin-145.0%
FCF margin-221.7%
EBITDA margin-147.5%

Returns

ROE-147.4%
ROA-34.3%
ROIC (approx.)—
Asset turnover0.24x

Leverage & solvency

Liabilities / assets61.5%
Debt / equity0.67x
Current ratio2.82x
Interest coverage-10.58x

Cash quality & payout

Operating cash flow / net income1.53x
Accruals ratio18.0%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$10.37M$11.89M$2.83M$24.74M$7.54M$3.58M$4.66M$30.60M
R&D expense$21.17M$20.18M$17.60M$27.40M$19.77M$16.18M$26.59M$48.61M
SG&A expense$13.48M$11.60M$10.23M$11.35M$12.32M$12.86M$13.38M$16.35M
Operating income-$24.28M-$18.55M-$25.00M-$7.75M-$24.55M-$51.54M-$76.16M-$46.59M
Interest expense$1.08M$1.06M$5.00M$0$2.40M$2.02M$2.13M$2.13M
Net income-$23.39M-$18.23M-$24.98M-$5.62M-$25.12M-$53.23M-$76.09M-$45.40M
EBITDA-$23.90M-$18.14M-$24.52M-$6.95M-$23.83M-$49.71M-$74.25M-$45.21M
EPS (basic)-0.15-0.15-0.26—-0.28-0.63-0.92—
EPS (diluted)-0.15-0.15-0.26—-0.28-0.63-0.92—
Weighted avg. shares (diluted)153.60M119.29M97.88M—90.09M84.41M83.06M—
Balance sheet
Cash & equivalents$93.17M$181.81M$123.65M$146.65M$165.65M$138.54M$138.69M$135.42M
Short-term investments$97.03M$29.83M—$0$0$39.96M$82.27M$138.37M
Receivables$7.73M$2.73M$2.59M$15.18M$8.13M$588,000$510,000$16.27M
Current assets$201.97M$218.07M$128.07M$163.90M$176.89M$182.80M$224.84M$289.31M
PP&E, net$2.19M$2.57M$2.88M$3.54M$4.29M$4.58M$8.18M$14.50M
Total assets$219.41M$237.36M$149.34M$186.53M$201.75M$210.58M$263.65M$341.59M
Current liabilities$71.58M$68.43M$39.78M$46.25M$61.77M$65.94M$73.11M$77.22M
Short-term debt$7.50M$7.50M$7.50M$5.00M$5.00M$5.00M$5.00M$5.00M
Long-term debt$49.32M$48.24M$47.18M$53.60M$54.07M$51.67M$49.58M$52.43M
Total debt$56.82M$55.74M$54.68M$58.60M$59.07M$56.67M$54.58M$57.43M
Total liabilities$134.89M$132.08M$144.93M$159.25M$188.30M$191.39M$201.23M$207.31M
Shareholders' equity$84.52M$105.28M$4.41M$27.29M$13.45M$19.19M$62.42M$134.27M
Net debt-$36.35M-$126.08M-$68.97M-$88.04M-$106.58M-$81.87M-$84.11M-$77.98M
Shares outstanding97.87M97.87M97.87M97.87M93.26M87.39M83.71M82.73M
Cash flow statement
Operating cash flow-$21.19M-$29.57M-$23.06M-$36.39M-$30.84M-$50.21M-$47.80M-$50.76M
Capital expenditure$0$106,000$92,000$60,000$433,000$0$114,000$540,000
Free cash flow-$21.19M-$29.67M-$23.15M-$36.45M-$31.28M-$50.21M-$47.91M-$51.30M
Investing cash flow-$66.99M-$29.80M$64,000$58,000$39.57M$42.65M$56.39M$30.96M
Financing cash flow-$468,000$117.53M$0$17.33M$17.17M$7.41M-$1.44M$55.51M
Depreciation & amortization$385,000$416,000$483,000$805,000$721,000$1.83M$1.92M$1.38M
Stock-based compensation$2.57M$2.19M$2.10M$2.13M$2.23M$2.66M$2.98M$4.02M

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.